Misomal (artesunate + sulfadoxine + pyrimethamine): Uses, Dosage & Side Effects

What it's for (Indications)

Artesunate + Sulfadoxine + Pyrimethamine (e.
g.
, Malasunate) is primarily indicated for the treatment of uncomplicated Plasmodium falciparum malaria in geographical regions where the parasite remains susceptible to this artemisinin-based combination therapy (ACT).
This combination is crucial in areas with documented resistance to monotherapy or older antimalarial regimens.
As an ACT, it leverages the rapid parasiticidal action of artesunate to quickly reduce parasite biomass and symptoms, complemented by the sustained inhibitory effects of sulfadoxine and pyrimethamine to prevent recrudescence.
Its use must align with current national and international malaria treatment guidelines, which consider local resistance patterns and epidemiological data to ensure optimal efficacy and prevent further drug resistance development.
It is typically reserved for cases where single-agent antimalarials are no longer effective.

Dosage Information

Type	Guideline
Standard	The dosage of Artesunate + Sulfadoxine + Pyrimethamine must be determined by a healthcare professional based on the patient's age, body weight, and national treatment guidelines for uncomplicated Plasmodium falciparum malaria. Typically, artesunate is administered orally once daily for three days, while sulfadoxine-pyrimethamine is given as a single oral dose on the first day of treatment, often concurrently with the initial dose of artesunate. For example, a common adult dose might involve 100 mg of artesunate per day for three days, alongside a single dose of 500 mg sulfadoxine and 25 mg pyrimethamine. Pediatric dosages are meticulously calculated per kilogram of body weight to ensure efficacy and minimize adverse effects. Adherence to the complete prescribed regimen is critical to achieve radical cure, prevent treatment failure, and minimize the development of drug resistance. Patients must be advised on proper administration, including taking the medication with food to enhance absorption and reduce gastrointestinal upset.

Type

Guideline

Standard

The dosage of Artesunate + Sulfadoxine + Pyrimethamine must be determined by a healthcare professional based on the patient's age, body weight, and national treatment guidelines for uncomplicated Plasmodium falciparum malaria. Typically, artesunate is administered orally once daily for three days, while sulfadoxine-pyrimethamine is given as a single oral dose on the first day of treatment, often concurrently with the initial dose of artesunate. For example, a common adult dose might involve 100 mg of artesunate per day for three days, alongside a single dose of 500 mg sulfadoxine and 25 mg pyrimethamine. Pediatric dosages are meticulously calculated per kilogram of body weight to ensure efficacy and minimize adverse effects. Adherence to the complete prescribed regimen is critical to achieve radical cure, prevent treatment failure, and minimize the development of drug resistance. Patients must be advised on proper administration, including taking the medication with food to enhance absorption and reduce gastrointestinal upset.

Safety & Warnings

Common Side Effects

Commonly reported side effects for Artesunate + Sulfadoxine + Pyrimethamine include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea.
Other frequent, generally mild, reactions may involve headache, dizziness, fatigue, and skin rash.
However, more severe and potentially life-threatening adverse drug reactions can occur, primarily due to the sulfadoxine-pyrimethamine component.
These include severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), which necessitate immediate medical attention and drug discontinuation.
Hematologic toxicities like agranulocytosis, aplastic anemia, hemolytic anemia (especially in G6PD deficient individuals), megaloblastic anemia, and thrombocytopenia are also significant concerns.
Hepatic dysfunction, including elevated liver enzymes and hepatitis, and renal impairment have also been reported.
Patients should be monitored for any signs of hypersensitivity or serious adverse events.

Serious Warnings

Black Box Warning: **SERIOUS WARNINGS: SEVERE CUTANEOUS AND HEMATOLOGIC ADVERSE REACTIONS** Sulfadoxine-Pyrimethamine, a component of this combination therapy, has been associated with severe, life-threatening, and sometimes fatal adverse reactions, including severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). These reactions can occur at any time during treatment but are most common early in therapy. Patients should be instructed to discontinue treatment immediately and seek urgent medical attention at the first appearance of skin rash, mucosal lesions, fever, facial swelling, or lymphadenopathy. Early withdrawal is critical for mitigating the severity of these reactions. Furthermore, serious hematologic toxicities, including agranulocytosis, aplastic anemia, and megaloblastic anemia, have been reported. Complete blood counts should be monitored regularly, particularly in patients with pre-existing hematologic abnormalities or prolonged treatment. Any signs of bone marrow suppression, such as unexplained fatigue, bruising, or fever, necessitate immediate discontinuation and thorough investigation. The risks associated with these severe reactions must be carefully weighed against the benefits of treatment, especially in areas with established drug resistance patterns where alternative effective therapies may be limited.
Severe warnings are associated with the use of Artesunate + Sulfadoxine + Pyrimethamine, particularly concerning the sulfadoxine-pyrimethamine component.
Patients with known hypersensitivity to sulfonamides, pyrimethamine, or any component of the formulation should not receive this medication due to the risk of severe allergic reactions, including anaphylaxis.
The potential for severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), requires immediate cessation of treatment at the first sign of rash.
Hematologic toxicities, including agranulocytosis, aplastic anemia, and megaloblastic anemia, are serious risks, necessitating careful monitoring of blood counts, especially in patients with pre-existing hematologic disorders or folate deficiency.
Caution is advised in patients with impaired hepatic or renal function, and dose adjustments may be necessary.
Furthermore, the drug should be used with extreme caution in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolytic anemia.
Concurrent use with other antifolate drugs or myelosuppressive agents should be avoided due to additive toxicity.
Patients must be educated on potential adverse effects and advised to seek immediate medical attention if any serious symptoms arise.

How it Works (Mechanism of Action)

Artesunate + Sulfadoxine + Pyrimethamine is an artemisinin-based combination therapy (ACT) that employs a multi-pronged approach to combat Plasmodium falciparum malaria. Artesunate, an artemisinin derivative, is a highly potent and fast-acting schizonticidal agent. It is activated by parasitic heme iron, leading to the formation of highly reactive free radicals (e.g., carbon-centered radicals) that alkylate and damage key parasitic proteins and membranes, including enzymes involved in heme detoxification and parasite calcium ATPases. This rapid action results in quick parasite clearance and resolution of clinical symptoms. Sulfadoxine and pyrimethamine act synergistically by inhibiting two sequential enzymes in the parasitic folate synthesis pathway. Sulfadoxine is a dihydropteroate synthase (DHPS) inhibitor, preventing the incorporation of para-aminobenzoic acid (PABA) into dihydrofolic acid. Pyrimethamine is a dihydrofolate reductase (DHFR) inhibitor, blocking the reduction of dihydrofolate to tetrahydrofolate. The combined inhibition of these crucial steps leads to a potent blockade of nucleic acid synthesis and cell replication in the parasite, preventing its growth and proliferation. This synergistic effect overcomes some levels of individual drug resistance and enhances overall antimalarial efficacy.